Want to see GHRS full AI Analyst Report?

GH Research (GHRS) Price & Analysis

366 Followers

GHRS Stock Chart & Stats

$18.34

-$0.22(-2.41%)

At close: Jan 08 4:00 PM EST

$18.34

-$0.22(-2.41%)

Day’s Range― - ―

52-Week Range$11.32 - $25.94

Previous CloseN/A

Volume14.35K

Average Volume (3M)245.16K

Market Cap

$1.84B

Enterprise Value$1.25B

Total Cash (Recent Filing)$267.32M

Total Debt (Recent Filing)$432.00K

Price to Earnings (P/E)―

Beta1.13

Next Earnings

Aug 26, 2026

EPS Estimate

-0.32

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.92

Shares Outstanding68,557,175

10 Day Avg. Volume254,669

30 Day Avg. Volume245,164

Financial Highlights & Ratios

PEG Ratio-3.01

Price to Book (P/B)2.77

Price to Sales (P/S)0.00

P/FCF Ratio-17.75

Enterprise Value/Market Cap0.68

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-3.56K

Enterprise Value/Ebitda-22.30

Forecast

1Y Price Target

$41.67

Price Target Upside127.19% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

EPS Forecast (FY)-1.41

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Strong Balance Sheet, Low LeverageVery low debt and substantial equity provide a durable financial cushion that supports continued R&D and clinical programs without immediate refinancing. This strengthens negotiating leverage for partnerships and gives the company structural runway to advance trials absent product revenue.

Completed $111M Equity RaiseA material $111M capital injection meaningfully extends the company’s ability to fund late-stage trials, pre-commercial activities and technical development. This reduces near-term financing pressure and supports program execution over the coming 2–6 months.

Peer-reviewed Phase 2a Results And Scientific VisibilityPeer-reviewed rapid-remission data and conference acceptances increase scientific credibility and de-risk the GH001 program if replicated in larger trials. Durable benefits include stronger clinician awareness, easier patient recruitment and improved partner licensing discussions.

Bears Say

No Revenue; Widening Net LossesPersistent lack of product revenue and widening losses reflect a development-stage profile that will continue to consume capital until commercialization. Over months this raises execution and funding risk and constrains reinvestment capacity without external financing or partnerships.

Rising Negative Operating Cash FlowMaterially increasing cash burn from R&D and operations reduces runway and forces the company to seek additional capital. Structural negative cash flow heightens dilution or debt risk and can limit strategic optionality if clinical timelines slip.

Dependence On Dilutive Equity Financing (ATM Access)An active ATM and recent follow-on issuance show reliance on equity markets to fund operations. While providing flexibility, ongoing access to dilutive capital is a structural risk that can erode existing shareholders' value if product commercialization is delayed.

GH Research News

Psychedelic: Enveric initiates IND-enabling genotoxicity studies of EB-003

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on...

27d ago

CMND

ENVB

GH Research announces publication of Phase 2a results for mebufotenin

GH Research (GHRS) announced the publication of the full results from its Phase 2a trial in postpartum depression...

27d ago

GHRS

GH Research Shareholders Approve Director Slate and 2026 Auditor at June AGM

GH Research ( ($GHRS) ) just unveiled an announcement. On June 25, 2026, GH Research PLC held its...

5d ago

GHRS

GH Research Publishes Positive Phase 2a Postpartum Depression Data and Secures CINP 2026 Slots for GH001

An update from GH Research ( ($GHRS) ) is now available. On June 4, 2026, GH Research PLC...

27d ago

GHRS

Psychedelic: Enveric, NRx, Bright Minds report quarterly earnings

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on...

1M ago

CMND

CMPS

GH Research to Present New GH001 Phase 2b Data in Treatment-Resistant Depression at ASCP 2026

GH Research ( ($GHRS) ) has provided an announcement. GH Research PLC will showcase new Phase 2b data...

1M ago

GHRS

GH Research price target lowered to $65 from $70 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on GH Research (GHRS) to $65 from $70 and keeps a...

1M ago

GHRS

GH Research price target raised to $35 from $25 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on GH Research (GHRS) to $35 from $25 and keeps an...

2M ago

GHRS

GH Research price target lowered to $39 from $42 at Citizens

Citizens analyst Jason Butler lowered the firm’s price target on GH Research (GHRS) to $39 from $42 and...

2M ago

GHRS

GH Research Launches $200 Million At-the-Market Share Offering With Stifel

An announcement from GH Research ( ($GHRS) ) is now available. On May 14, 2026, GH Research PLC...

2M ago

GHRS

Psychedelic: Compass Pathways, AtaiBeckley, GH Research report earnings

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on...

2M ago

ATAI

CMND

GH Research files $400M mixed securities shelf

09:22 EDT GH Research (GHRS) files $400M mixed securities shelf Published first on TheFly – the ultimate source...

2M ago

GHRS

GH Research reports Q1 EPS (31c), consensus (26c)

“The first quarter of 2026 marks progress as planned toward our global GH001 Phase 3 pivotal program,” said...

2M ago

GHRS

GH Research Posts Wider Q1 2026 Loss as R&D and Admin Costs Rise

GH Research ( ($GHRS) ) has provided an announcement. On May 14, 2026, GH Research PLC filed a...

2M ago

GHRS

GHRS FAQ

What was Gh Research Plc’s price range in the past 12 months?

Gh Research Plc lowest stock price was $11.32 and its highest was $25.94 in the past 12 months.

What is Gh Research Plc’s market cap?

Gh Research Plc’s market cap is $1.84B.

When is Gh Research Plc’s upcoming earnings report date?

Gh Research Plc’s upcoming earnings report date is Aug 26, 2026 which is in 56 days.

How were Gh Research Plc’s earnings last quarter?

Gh Research Plc released its earnings results on May 14, 2026. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.293 by -$0.017.

Is Gh Research Plc overvalued?

According to Wall Street analysts Gh Research Plc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Gh Research Plc pay dividends?

Gh Research Plc does not currently pay dividends.

What is Gh Research Plc’s EPS estimate?

Gh Research Plc’s EPS estimate is -0.32.

How many shares outstanding does Gh Research Plc have?

Gh Research Plc has 68,557,175 shares outstanding.

What happened to Gh Research Plc’s price movement after its last earnings report?

Gh Research Plc reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.293. Following the earnings report the stock price went up 1.508%.

Which hedge fund is a major shareholder of Gh Research Plc?

Currently, no hedge funds are holding shares in GHRS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

GH Research Stock Smart Score

Neutral

Fundamentals

Return on Equity

-19.83%

Trailing 12-Months

Asset Growth

-14.10%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Gh Research Plc

GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.

GH Research (GHRS) Earnings & Revenues

Historic Earnings Reports

GHRS Stock 12 Month Forecast

Average Price Target

$41.67

▲(127.19% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","24":"$24","38":"$38","52":"$52","66":"$66"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":65,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$65.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":41.666666666666664,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$41.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$32.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10,24,38,52,66],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.83,27.919999999999998,31.009999999999998,34.1,37.19,40.28,43.370000000000005,46.46,49.55,52.64,55.730000000000004,58.82,61.910000000000004,{"y":65,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.83,26.125128205128203,27.420256410256407,28.715384615384615,30.01051282051282,31.305641025641023,32.60076923076923,33.89589743589744,35.19102564102564,36.48615384615384,37.78128205128205,39.076410256410256,40.371538461538464,{"y":41.666666666666664,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.83,25.38153846153846,25.93307692307692,26.484615384615385,27.036153846153844,27.587692307692308,28.139230769230767,28.69076923076923,29.24230769230769,29.793846153846154,30.345384615384614,30.896923076923077,31.448461538461537,{"y":32,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.56,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.72,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.74,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.93,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.57,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.32,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.21,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.7,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.82,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.01,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.72,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.71,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.83,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >